Alnylam Pharmaceuticals (GB:0HD2)

Alnylam Pharma (0HD2) Financial Statements


Alnylam Pharma Financial Overview

Alnylam Pharma's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Alnylam Pharma is scheduled to report earnings on July 31, 2024, and the estimated EPS forecast is $-1.05. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 439.72M$ 750.53M$ 305.70M$ 319.29M$ 599.42M
Gross Profit$ 353.86M$ 671.06M$ 253.45M$ 264.42M$ 548.16M
EBIT$ -106.35M$ 181.63M$ -244.17M$ -143.41M$ 88.29M
EBITDA$ -82.38M$ 191.84M$ -233.91M$ -131.39M$ 98.87M
Net Income Common Stockholders$ -137.87M$ 157.43M$ -276.02M$ -174.10M$ 56.90M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.44B$ 2.41B$ 2.06B$ 2.07B$ 2.19B
Total Assets$ 3.83B$ 3.84B$ 3.40B$ 3.39B$ 3.55B
Total Debt$ 1.31B$ 1.31B$ 1.31B$ 1.32B$ 1.32B
Net Debt$ -1.13B$ -1.10B$ -743.17M$ -750.33M$ -872.16M
Total Liabilities$ 4.05B$ 4.00B$ 3.81B$ 3.65B$ 3.55B
Stockholders Equity$ -220.64M$ -165.87M$ -408.13M$ -259.24M$ -158.22M
Cash Flow-
Free Cash Flow$ -45.10M$ 342.32M$ -74.91M$ -180.37M$ -153.61M
Operating Cash Flow$ -29.80M$ 359.41M$ -58.99M$ -166.47M$ -131.98M
Investing Cash Flow$ -240.66M$ -10.76M$ -8.71M$ -76.22M$ -139.91M
Financing Cash Flow$ 39.23M$ 33.14M$ 53.39M$ 46.37M$ 63.44M
Currency in USD

Alnylam Pharma Earnings and Revenue History

Alnylam Pharma Debt to Assets

Alnylam Pharma Cash Flow

Alnylam Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis